Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 11492650
    Abstract: Polypeptides that fold into biologies are stabilized by diselenide bonds between selenocysteine amino acids. Methods to produce such polypeptides in genomically recoded organisms (GRO) can be scaled up for industrial production. Since diselenides have the same geometric bond angles and torsions as disulfides, as well as very similar bond lengths, they can be substituted into polypeptides without disrupting the three dimensional structure of the polypeptides. Diselenides render the polypeptides resistant to reduction when they are exposed to blood serum or to reducing components of blood serum or to reducing components components within cells.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: November 8, 2022
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Daniel J. Mandell, Christopher John Gregg, Ross Thyer, Andrew D. Ellington, Peter Benjamin Stranges
  • Patent number: 11486874
    Abstract: Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: November 1, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Steven W. Taylor, Michael McPhaul, Richard E. Reitz, Zhaohui Chen, Nigel Clarke
  • Patent number: 11471540
    Abstract: The present invention relates to a gene delivery complex comprising: a biocompatible polymer backbone; and pegylated lactoferrin connected to the biocompatible polymer backbone by means of a covalent bond. The gene delivery complex is orally administered into an individual, can be absorbed in vivo by means of a lactoferrin receptor, and enables the in vivo delivery of a target gene and the expression thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 18, 2022
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Dong Yun Lee, Chang Woo Lee, Seungah Lee
  • Patent number: 11467167
    Abstract: Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: October 11, 2022
    Assignee: Biodesix, Inc.
    Inventors: Paul E. Kearney, Xiao-Jun Li, Clive Hayward
  • Patent number: 11428696
    Abstract: The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partne
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: August 30, 2022
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Albrecht Moritz, John Edward Rush, II, Roberto Polakiewicz
  • Patent number: 11414462
    Abstract: The present application relates to methods and compositions and methods for treating viral infections, especially those caused by SARS-CoV-2. In one aspect, a method of treatment comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a multipartite SARS-CoV-2-inhibiting peptide comprising a secretion modulating region (VI-SMR) peptide from HIV-1 Nef in combination with a cell-penetrating peptide (CPP) domain, a Clusterin (Clu)-binding peptide (Clu-BP) domain, a mitochondrial targeting (Mito-T) peptide domain, an anti-fusogenic (AF) peptide domain, a viral attachment inhibitor (VAI) domain or combination thereof, optionally where the SARS-CoV-2-inhibiting peptide is pegylated and/or modified with one or more hydrophobic domains.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: August 16, 2022
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent C. Bond, Ming Bo Huang, James W. Lillard, Jr.
  • Patent number: 11370822
    Abstract: The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked to a MrgX2 agonist peptide; for example, (RADA)4 linked to proadrenomedullin-12 (PAMP-12).
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 28, 2022
    Assignees: The Governors of the University of Alberta, National Research Council of Canada
    Inventors: Larry D. Unsworth, Lei Lu, Marianna Kulka
  • Patent number: 11357817
    Abstract: Methods and pharmaceutical compositions for treating malaria and immune related disorders are provided. The pharmaceutical compositions include an effective amount a carmaphycin B analog that inhibits immunoproteasome activity in a subject.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: June 14, 2022
    Assignee: The Regents of the University of California
    Inventors: William Gerwick, Betsaida Bibo Verdugo, Anthony O'Donoghue, Jehad Almaliti
  • Patent number: 11352394
    Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-hairpin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 7, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Patent number: 11339197
    Abstract: A modified EGF protein, a production method therefor, and a use thereof are disclosed. The modified EGF protein allows an effective delivery of EGF into the cell and exhibits an enhanced half-life span. A method for producing the modified EGF protein includes culturing conditions where host cell growth phase and protein expression phase employ different temperature conditions. A use of the modified EGF protein is also disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 24, 2022
    Assignee: PROGEN CO., LTD.
    Inventors: Zungyoon Yang, Eun Joo Nam
  • Patent number: 11339205
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: May 24, 2022
    Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Patent number: 11324796
    Abstract: Provided are a method for promoting the lipolysis and fatty acid oxidative metabolism in mammals or cells derived from mammals, a method for downregulating the fat content and the weight of a mammalian body, as well as a method for increasing the intracellular cAMP concentration, increasing the phosphorylation degree and the activity of the hormone-sensitive esterase HSL, enhancing the transcription activity of PPAR alpha and increasing the activities of enzymes involved in a fatty acid beta oxidation process. By simulating the expression of a protein corresponding to a gene responsible for the phosphorylation of the Fas-associated death domain protein, or treating and acting on mammals or cells derived from mammals with a material that can increase the phosphorylation degree of the Fas-associated death domain protein, said methods increases the phosphorylation of the Fas-associated death domain protein.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: May 10, 2022
    Assignee: Nanjing University
    Inventors: Hua Zichun, Zhuang Hongqin
  • Patent number: 11318187
    Abstract: This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-?1) or transforming growth factor beta 2 (TGF-?2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: May 3, 2022
    Inventor: Bjorn Eek
  • Patent number: 11318208
    Abstract: The present invention relates to a synthetic compound comprising at least one effector moiety and at least one binder moiety, wherein the effector moiety is associated to the binder moiety, and wherein further the effector moiety comprises a N-formyl methionine peptide which comprises an isoleucine residue (FIG. 1).
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 3, 2022
    Assignee: SYNTAB THERAPEUTICS GMBH
    Inventors: Christian Becker, Manuel Brehs, Karine Thewes, Ute Steinbusch, Andre J G Pötgens, Janett Schwarz
  • Patent number: 11312748
    Abstract: Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: April 26, 2022
    Assignee: AGENSYS, INC.
    Inventors: Brian Alan Mendelsohn, Julien Dugal-Tessier, Stuart Daniel Barnscher
  • Patent number: 11311604
    Abstract: The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 26, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Kennett Sprogøe, Frank Faltinger, Thomas Wegge, Felix Cleemann
  • Patent number: 11306313
    Abstract: A series of peptides and a peptide-siRNA complex are disclosed, wherein the peptide based complex effectively enhances delivery of siRNA molecules into the cells and release of siRNA in the cell, and improves siRNA mediated gene silencing efficiency of cellular targets. Pharmaceutical compositions that include the complex, as well as a use of the complex in the gene therapy field, are also disclosed.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 19, 2022
    Assignees: Positec Power Tools (Suzhou) Co LTD
    Inventors: Pu Chen, Dafeng Chu, Baoling Chen, Wen Xu, Ran Pan
  • Patent number: 11299514
    Abstract: The present disclosure discloses an antimicrobial peptide AS-hepc3(48-56) of Acanthopagrus schlegelii and method thereof. A molecular formula of the antimicrobial peptide AS-hepc3(48-56) is C48H86N24O10S3, and an amino acid sequence of the antimicrobial peptide AS-hepc3(48-56) is SEQ ID NO: 01.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: April 12, 2022
    Assignee: Xiamen University
    Inventors: Kejian Wang, Depeng Zhu, Hui Peng, Fangyi Chen, Huiyun Chen
  • Patent number: 11286278
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: March 29, 2022
    Assignee: Arch BioPartners, Inc.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
  • Patent number: 11286280
    Abstract: Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 29, 2022
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi